NEW YORK and SUZHOU, China, Sept. 4, 2025 /PRNewswire/ -- Accro Bioscience (Accropeutics), a clinic...
* Phase 2 primary endpoint of PASI-75 and key secondary endpoints met in all of the three dosing ...
* Approximately $12 million additional financing led by Shenzhen Capital Group (SCGC), with parti...
NEW YORK, Feb. 13, 2025 /PRNewswire/ -- Accropeutics Inc. (Accropeutics), a clinical-stage biotechn...
* Company to conduct a Phase II multi-regional clinical trial (MRCT) for the treatment of Ulcerat...
SUZHOU, China, May 24, 2023 /PRNewswire/ -- Accropeutics Bioscience announced that its oral small m...